ElendiLabs Logo
Back to Articles

Need Regulatory Help? Try Our Platform

Post your regulatory questions or request quotations from verified pharmaceutical consultants worldwide. Get matched with experts who specialize in your market.

Post Market Surveillance

June 16, 2025

Approximately 5 minutes

Post-Market Surveillance and Adverse Event Reporting in Malaysia: MDA Vigilance Requirements

Post-Market Surveillance and Adverse Event Reporting in Malaysia: MDA Vigilance Requirements

Post-Market Surveillance (PMS) is a mandatory requirement for all manufacturers selling medical devices in Malaysia. This vigilance system is enforced by the Medical Device Authority (MDA) under the Medical Device Act 2012 and the Medical Device (Duties and Obligations of Establishment) Regulations 2019. Failure to comply with these requirements, which are similar to those in the ASEAN Medical Device Directive (AMDD), can result in product recall or loss of market access.


The Role of the Authorized Representative

The Malaysia Authorized Representative (AR), or license holder, whose details are listed on the product's registration certificate, holds a critical responsibility in the PMS process. The AR is the legally responsible entity for communicating with the MDA on behalf of the foreign manufacturer regarding all post-market vigilance issues, including Adverse Event (AE) reporting and Field Safety Corrective Actions (FSCAs).

Criteria for Reportable Adverse Events (AEs)

An event is considered a reportable Adverse Event (AE) only if three core criteria are met:

  1. An Adverse Event has occurred.
  2. The medical device is associated with the Adverse Event.
  3. The Adverse Event led to one of the following serious outcomes:
    • A serious threat to public health.
    • Death or serious deterioration in the state of health of a patient, user, or other person.
    • No death or serious injury occurred, but the event, if it recurs, might lead to death or serious injury of a patient, user, or other person.

Mandatory Reporting Timelines

All Adverse Events must be reported to the MDA immediately and within the following specific timeframes, calculated from the moment the manufacturer or their AR becomes aware of the event:

Event TypeReporting Deadline
Serious threat to public healthNot later than 48 hours
Death or serious deterioration in state of healthNot later than 10 days
Recurrence might lead to death or serious injuryNot later than 30 days

Post-Market Corrective Actions (FSCAs)

In addition to reporting, manufacturers are obligated to implement Field Safety Corrective Actions (FSCAs) if necessary. The AR is responsible for managing the communication and implementation of these corrective actions in collaboration with the MDA to ensure device safety and compliance in the Malaysian market.

Ask Anything

We'll follow up with you personally.

100% response rate • Reply within 7 business days

Your email will not be published. We'll only use it to notify you when we respond.

Need Expert Guidance?

Contact us at contact@elendilabs.com / +852 4416 5550